Diverticulitis Market SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024 - 2031)

Diverticulitis Market Size - Analysis

Diverticulitis Market Trends

As population ages globally, the prevalence of diverticulitis is set to rise significantly in the coming years. Diverticulitis commonly occurs in aging population where diverticula tend to form in the weakened colon walls due to aging. People above 60 years of age have higher chances of developing diverticulitis compared to younger population. With worldwide average life expectancy increasing over time and percentage of elderly population growing rapidly, it is highly likely that cases of diverticulitis will surge exponentially.

Ever since laparoscopic colectomy was introduced for diverticulitis treatment in 1990s, it has gained widespread acceptance due to significant advantages over open surgeries. Minimally invasive procedures cause little damage to muscles and tissues compared to open surgery requiring large incisions. This results in less postoperative pain, quick recovery times, lesser hospital stay and lower risks of surgical site infections. Patients also benefit from smaller scars and improved cosmetic outcomes.

Constant innovation is underway to develop newer surgical robots with autonomous capabilities and augmented reality features. Surgical staplers, tissue graspers and energy devices are also becoming more compact and advanced and even start incorporating artificial intelligence. As minimally invasive surgeries for diverticulitis demonstrate continuously better clinical outcomes, adoption rates are accelerating. This rapidly evolving landscape provides ongoing momentum to diverticulitis treatment market.

Diverticulitis is a fairly common condition that often requires surgical intervention for treatment. While there have been advancements in minimally invasive techniques, many procedures still carry a high price tag. This represents a challenge as not all patients, especially those in developing nations or without adequate health insurance, may be able to afford the costs associated.

As a result, some individuals may delay or avoid necessary interventions. This poses health risks and also impacts the potential patient pool for pharmaceutical manufacturers targeting this market. High procedure prices could impede broader market growth potential.

Market Opportunity - Growing Healthcare Infrastructure in Developing Countries Presents New Growth Avenues for Market

A growing middle class has more disposable income available for healthcare spending. At the same time, biopharmaceutical companies and medical device manufacturers are paying greater attention to these regions as venues for sales and clinical trials.

Prescribers preferences of Diverticulitis Market

Diverticulitis is typically treated based on its stage and severity. For uncomplicated acute diverticulitis, prescribers commonly recommend oral antibiotics such as amoxicillin/clavulanate (Augmentin) to treat the infection. If symptoms do not improve within a few days, or are severe, patients may be switched to intravenous antibiotics like piperacillin/tazobactam (Zosyn).

For complicated diverticulitis with abscesses or bowel perforations, broad-spectrum IV antibiotics along with computed tomography (CT) scans are immediately used. Depending on CT findings, surgeons may drain or remove abscesses percutaneously using image-guidance. For non-resolving complications or those with bowel obstructions, sigmoidectomy (removal of the sigmoid colon) is commonly performed.

Treatment Option Analysis of Diverticulitis Market

Diverticulitis has three main stages - mild, moderate, and severe. The treatment approach varies depending on the stage.

In cases of moderate diverticulitis with abscess formation, antibiotics alone may not be sufficient. The standard treatment involves antibiotic therapy along with minimally invasive surgery such as CT-guided drainage of abscesses. Larger abscesses (>4cm) often require surgical drainage either laparoscopically or through small incisions.

Selecting the appropriate treatment depends on accurate staging. While antibiotics remain the first-line intervention for mild cases, drainage or resection becomes necessary for moderate to severe episodes to prevent complications like fistula or stricture formation. A multi-disciplinary approach combining antibiotics, radiology-guided procedures, and surgery achieves optimal outcomes.

Key winning strategies adopted by key players of Diverticulitis Market

One of the major strategies adopted by pharmaceutical companies has been investing heavily in R&D to develop novel drugs for treating diverticulitis. For example, in 2019, Abbott Laboratories received FDA approval for their drug Entivyo (vedolizumab) for the treatment of mildly to moderately active ulcerative colitis in pediatric patients.

Acquisitions and partnerships for pipeline expansion

Given the rising disease prevalence in developing nations, players are focusing on markets like Asia Pacific, Latin America, and Middle East & Africa through tailored regulatory and commercial strategies. For instance, between 2015-19, Takeda Pharmaceuticals invested over $150 million in clinical trials and business development across Asia to prepare for launch of their IBD drug portfolio.

Adoption of new technologies

Segmental Analysis of Diverticulitis Market

In terms of treatment, medical therapy is estimated to hold 68.4% of market share in 2024, owing to increasing healthcare expenditure and better access to treatment options. Medical therapy is usually the first line of treatment for diverticulitis as it is non-invasive and has minimal risks. It involves antibiotics to treat infection, pain relievers to manage symptoms, and fiber supplements to regulate bowel movements.

In terms of diagnosis method, imaging tests are estimated to account for 57.8% of market share in 2024, due to advances in diagnostic imaging technologies. CT scans and ultrasound have become highly effective in detecting diverticulitis by visualizing structures of the digestive system. CT scans provide detailed images of the abdomen allowing accurate diagnosis. Advancing CT scan technologies have automated processes, improved image quality, reduced radiation dosage and scan time.

Insights, By End User: Infrastructure Expansion Drives Hospitals as the Prime End User

An increasing number of beds, diagnostic centers and operating rooms in hospitals can effectively manage diverticulitis patients. Hospitals also provide round-the-clock emergency services for complicated cases. As patients increasingly rely on hospitals for quick and comprehensive care, their demand for diverticulitis services has grown the most within hospitals.

Additional Insights of Diverticulitis Market

• Studies indicate that about 25% of patients with diverticulosis may develop diverticulitis at some point in their lives.
• The adoption of high-fiber diets has been recommended as a preventive measure, influencing market trends toward dietary management products.

Competitive overview of Diverticulitis Market

The major players operating in the diverticulitis market include Takeda Pharmaceutical Company Limited, AstraZeneca PLC, Allergan (now part of AbbVie), Bayer AG, Johnson & Johnson, Pfizer Inc., Novartis AG, GlaxoSmithKline PLC, Eli Lilly and Company, Merck & Co., Inc., AbbVie Inc., and Teva Pharmaceutical Industries Ltd.

Recent Developments in Diverticulitis Market

Diverticulitis Market Segmentation

• By Treatment
  • Medical Therapy
    • Antibiotics
    • Pain Relievers
    • Fiber Supplements
  • Surgical Procedures
    • Primary Bowel Resection
    • Bowel Resection with Colostomy
• By Diagnosis Method
  • Imaging Tests
    • CT Scans
    • Ultrasound
  • Laboratory Tests
    • Blood Tests
    • Stool Tests
• By End User
  • Hospitals
  • Ambulatory Surgical Centers
  • Specialty Clinics